Stay updated on Safety of CAN04 and Pembrolizumab in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the Safety of CAN04 and Pembrolizumab in Solid Tumors Clinical Trial page.
Latest updates to the Safety of CAN04 and Pembrolizumab in Solid Tumors Clinical Trial page
- Check2 days agoChange DetectedMinor formatting and UI adjustments observed; core study details such as inclusion criteria, outcomes, and enrollment appear unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%
- Check9 days agoChange DetectedThe page shows the addition of Revision: v3.3.4 and the deletion of Revision: v3.3.3. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedThe new screenshot shows the same Study Details page (NCT04452214) with no additions or deletions to core content; any differences seem to be minor formatting/layout adjustments. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%
- Check31 days agoChange DetectedAdded a dedicated Locations section listing Colorado, Florida, and Pennsylvania as study sites, and removed the separate per-state headers. The page now shows revision: v3.3.3.SummaryDifference0.5%
- Check38 days agoChange DetectedNo additions or deletions detected on the page; the content remains unchanged.SummaryDifference0.1%
- Check59 days agoChange DetectedRevision updated from v3.2.0 to v3.3.2 on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%
Stay in the know with updates to Safety of CAN04 and Pembrolizumab in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety of CAN04 and Pembrolizumab in Solid Tumors Clinical Trial page.